ACN - Company News

Press Releases


Monday, June 27, 2016

聯康生物科技與華潤紫竹就金因舒®達成戰略聯盟
聯康生物科技集團有限公司（「聯康生物科技」或「集團」；股份代號：690）今天宣佈，集團與華潤醫藥集團旗下專注於在國內開發、製造及銷售眼科及生殖健康用藥的全資附屬公司 ─ 華潤紫竹藥業有限公司（「華潤紫竹」）簽訂戰略聯盟協議。 more info >>

Uni-Bio Science Group Forges Strategic Alliance with China Resources Zizhu for GeneSoft
Uni-Bio Science Group Ltd (HKEx: 690) announced that it has signed a strategic alliance agreement with China Resources Zizhu Pharmaceutical Co., Ltd. more info >>

Tuesday, June 14, 2016

联康生物科技集团公布二零一五年全年业绩
联康生物科技集团有限公司（「联康生物科技」或「集团」；股份代号：690）宣布截至二零一五年十二月三十一日止年度之经审核全年业绩。 more info >>

Uni-Bio Science Group Announces 2015 Annual Results
Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has announced its audited annual results for the year ended 31 December 2015. more info >>

聯康生物科技集團公佈二零一五年全年業績
聯康生物科技集團有限公司（「聯康生物科技」或「集團」；股份代號：690）宣佈截至二零一五年十二月三十一日止年度之經審核全年業績。 more info >>

Tuesday, March 8, 2016

联康生物科技完成治疗贫血的Uni-EPO-Fc I期单剂量递增耐受性临床研究
联康生物科技集团有限公司（「联康生物科技」或「集团」；股份代号：0690）今天公布，其长效人促红细胞生成素-Fc 融合蛋白注射液（「Uni-EPO-Fc」）已完成I期耐受性单剂量递增的临床研究。 more info >>

聯康生物科技完成治療貧血的Uni-EPO-Fc I期單劑量遞增耐受性臨床研究
聯康生物科技集團有限公司（「聯康生物科技」或「集團」；股份代號：0690）今天公佈，其長效人促紅細胞生成素-Fc 融合蛋白注射液（「Uni-EPO-Fc」）已完成I期耐受性單劑量遞增的臨床研究。 more info >>

Uni-Bio Science Completes Phase I Single Ascending Dose (SAD) Tolerability Study of Uni-EPO-Fc for Treatment of Anaemia
Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group;" HKEx code: 690) today announced that its long-acting Human Erythropoietin-Fc fusion protein injection ("Uni-EPO-Fc") has successfully completed the single ascending dose tolerability study of the Phase I clinical trial. more info >>

Tuesday, November 24, 2015

联康生物科技从江苏豪森药业股份有限公司收购2型糖尿病药物米格列奈之全球权益
联康生物科技集团有限公司（「联康生物科技」或「集团」；股份代号：0690）今天宣佈，集团从江苏豪森药业股份有限公司（「豪森」）取得在全球生产及商业化新型口服抗糖尿病药物米格列奈（mitiglinide）的独家权利。 more info >>

聯康生物科技從江蘇豪森藥業股份有限公司收購2型糖尿病藥物米格列奈之全球權益
聯康生物科技集團有限公司（「聯康生物科技」或「集團」；股份代號：0690）今天宣佈，集團從江蘇豪森藥業股份有限公司（「豪森」）取得在全球生產及商業化新型口服抗糖尿病藥物米格列奈（mitiglinide）的獨家權利。 more info >>


1 2 3 4 5 6

Latest Press Releases

Spritzer Scores Big with 'Meet the Red Legends' Event for Football Fans Apr 28, 2024 18:00 HKT/SGT

Announcing Mad About Marketing - A New Member of the Digital Sukoon Private Limited Family Apr 28, 2024 17:00 HKT/SGT

HKTDC unveils gifts, printing, packaging and licensing events Apr 27, 2024 21:00: JST

HKTDC unveils gifts, printing, packaging and licensing events Apr 27, 2024 20:00 HKT/SGT

Masverse Unveils Groundbreaking Blockchain Platform Apr 27, 2024 02:40 HKT/SGT

Spritzer Scores Big with 'Meet the Red Legends' Event for Football Fans Apr 27, 2024 00:00: JST

Announcing Mad About Marketing - A New Member of the Digital Sukoon Private Limited Family Apr 26, 2024 23:25: JST

FinTech Funding Continues to Surge as Second Edition of Dubai FinTech Summit Commences Apr 26, 2024 21:10 HKT/SGT

汇聚科技有限公司公布截至二零二三年十二月三十一日止末期业绩 Apr 26, 2024 18:53 HKT/SGT

匯聚科技有限公司公佈截至二零二三年十二月三十一日止末期業績 Apr 26, 2024 18:43 HKT/SGT

UK advertising reports GBP36.6bn spend in 2023 Apr 26, 2024 18:30: JST

TIME Interconnect Technology Limited Announces Final Results For The Nine Months Ended 31 December 2023 Apr 26, 2024 18:26 HKT/SGT

UK advertising reports GBP36.6bn spend in 2023 Apr 26, 2024 17:30 HKT/SGT

CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine Apr 26, 2024 16:36: JST

CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine Apr 26, 2024 15:36 HKT/SGT


More News >>


Home \| About us \| Services \| Partners \| Events \| Login \| Contact us \| Cookies Policy \| Privacy Policy \| Disclaimer \| Terms of Use \| RSS

US: +1 214 890 4418 \| China: +86 181 2376 3721 \| Hong Kong: +852 8192 4922 \| Singapore: +65 6549 7068 \| Tokyo: +81 3 6859 8575